RespireRx Pharmaceuticals Inc (RSPI)

[Market_Fest4]

With all of the potential that Ampakines supposedly have, and a decent stock price 3 years ago, pre-FDA-botch.; It is testament to managements failure to bring value to the stockholder that the sp now sub.20

For this, Stoll and MV deserve an "F". Nothing here warrants continuing with the same management/model/plan etc. I hope a deal is announced on Monday. I fear that if a deal is announced it will be another pathetic deal that doesn't provide incentive for the partner to actively pursue development. It could be the kind of deal with a competitor that keeps AMPAs on the shelf and off the market until patent expiration.

Regardless, all the contributing factors keeping these molecules off the market has been a heart-breaking ride.
MF4